Aethlon Medical (NASDAQ:AEMD) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Aethlon Medical (NASDAQ:AEMD) in a report published on Friday morning. The brokerage issued a sell rating on the medical equipment provider’s stock.

Separately, HC Wainwright cut their target price on Aethlon Medical from $10.00 to $7.00 and set a buy rating for the company in a research note on Monday, June 24th.

Aethlon Medical Stock Performance

Aethlon Medical stock opened at $0.39 on Friday. Aethlon Medical has a fifty-two week low of $0.24 and a fifty-two week high of $2.80. The firm’s fifty day moving average price is $0.39 and its 200-day moving average price is $0.85. The stock has a market cap of $5.37 million, a P/E ratio of -0.08 and a beta of 1.72.

Aethlon Medical (NASDAQ:AEMD) last issued its quarterly earnings results on Wednesday, August 14th. The medical equipment provider reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.10. During the same period in the prior year, the business posted ($1.30) EPS. On average, analysts predict that Aethlon Medical will post -1.1 earnings per share for the current year.

About Aethlon Medical

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.